Posted by Michael Wonder on 27 Dec 2022
Acer Therapeutics and Relief Therapeutics announce US FDA approval of Olpruva for patients with urea cycle disorders
27 December 2022 - New FDA approved formulation for patients living with urea cycle disorders.
Acer Therapeutics and its collaboration partner, Relief Therapeutics, today announced that the US FDA has approved Olpruva (sodium phenylbutyrate) for oral suspension in the US for the treatment of certain patients living with urea cycle disorders involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase, or argininosuccinic acid synthetase.
